Dr. LoRusso on the Efficacy of BI 907828 in Solid Tumors

Supplements and Featured Publications, Diagnosis and Trial Options in Sarcoma, Volume 1, Issue 1

In Partnership With:

Partner | Cancer Centers | <b>Yale Cancer Center</b>

Patricia LoRusso, DO, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial.

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate cancer center director, Experimental Therapeutics, Yale School of Medicine, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial (NCT03449381).

This study evaluated adult patients with different types of advanced solid tumors to find the preferred dose of BI 907828.

Results from this trial showed patients achieved responses and a prolongation of stable disease, LoRusso says. Notably, the responses observed were durable, LoRusso adds.

In patients with MDM2 amplification, BI 907828 generated responses, regardless of the dosage administered or the schedule of treatment, LoRusso adds.

The low dose and high dose of BI 907828 will be further explored in the phase 2/3 Brightline-1 trial (NCT05218499) in patients with dedifferentiated liposarcoma, LoRusso concludes.